The Saladax Scientific Advisory Board has assembled a world-class team of experienced leaders in clinical and pharmacological oncology to support its growth and future strategy.
Joseph R. Bertino, M.D., Associate Director at The Cancer Institute of New Jersey and Professor of Medicine & Pharmacology at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School. Dr. Bertino was formerly Head of the Yale Cancer Center and more recently Chairman of Molecular Pharmacology and Therapeutics Program at the Sloan-Kettering Institute for Cancer Research.
Alec Goldenberg, M.D., Director, Hematology Clinic and Hepatoma Tumor Study Group, Bellevue Hospital, New York University Medical Center; Clinical Associate Professor of Medicine, New York University School of Medicine; and clinical practitioner. Dr. Goldenberg has 20 years of experience in clinical oncology practice with both Memorial Sloan Kettering and New York University.
Leslie M. Shaw, Ph.D., Director, Clinical Toxicology Laboratory and Xenobiotic Toxicokinetics Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center; Founder and Chair, Therapeutic Drug and Toxicology Monitoring Scientific Section of the American Society for Clinical Pharmacology and Therapeutics. He is past-President of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology between 1999 and 2001.